Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

The trial in the home setting evaluated a 120 mcg dose of BXCL501, the company’s proprietary, sublingual film formulation of dexmedetomidine, Igalmi, for agitation associated with bipolar disorders or schizophrenia.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.